WHO grants international non-proprietary name Melogliptin to Glenmark Pharmaceuticals's anti-diabetic drug
14 Jan 2008
Glenmark Pharmaceuticals Ltd today said that its lead candidate for type II diabetes, GRC 8200, "has received the international non-proprietary name (INN) Melogliptin, from the World Health Organization (WHO).
The company says this name was selected during the recently held 45th consultation on non-proprietary names and was made by the international panel for pharmacopoeia and pharmaceutical preparations.
GRC 82O0, Glenmark's lead DPPIV inhibitor, is a novel, oral DPPIV inhibitor in development for type 2 diabetes and is currently undergoing phase II clinical trials.
The drugmaker says that phase I studies showed that the compound was "very well tolerated by the subjects at all dosage levels and there were no significant adverse events reported".
It further added that more than 90 per cent inhibition of the DPP-IV enzyme was observed within one hour at all doses tested. In pre clinical studies, the compound appears to be effective and well tolerated when given at pharmacological doses.